INVESTABOT
Equity Research
XNYS · PHARMACEUTICAL PREPARATIONS · PHARMACEUTICAL PREPARATIONS
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
TL;DR: Abbott reported second-quarter 2026 revenue of $12.59B, up 13.0% from $11.14B a year ago, while raising its full-year adjusted EPS guidance range to $5.45–$5.60.
Abbott Laboratories (ABT) had 1 Form 144 pre-sale notice filed on 2026-05-15. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 8/12/2026 | Morrone Louis H. | EXECUTIVE VICE PRESIDENT | DISCRETIONARY | -12 | $108 | $1,296 |
| 8/11/2026 | Morrone Louis H. | EXECUTIVE VICE PRESIDENT | SELL | -5,850 | $110 | $642,506 |
| 6/30/2026 | Stratton John G | — | GRANT | 432 | $91 | $39,200 |
| 6/30/2026 | Roman Michael F | — | GRANT | 416 | $91 | $37,748 |
| 6/30/2026 | Gonzalez Patricia Paola | — | GRANT | 363 | $91 | $32,939 |
| 6/30/2026 | Conroy Kevin T | — | GRANT | 231 | $91 | $20,961 |
| 6/30/2026 | Ahuja Nita | — | GRANT | 347 | $91 | $31,487 |
| 6/30/2026 | Morrone Louis H. | EXECUTIVE VICE PRESIDENT | TAX_WITHHOLD | -269 | $93 | $24,939 |
| 6/27/2026 | Cushman Elizabeth C. | EVP, GC AND SECRETARY | TAX_WITHHOLD | -560 | $94 | $52,707 |
| 5/7/2026 | Stratton John G | — | BUY | 2,000 | $87 | $173,640 |
| 4/28/2026 | Moreland Mary K | EXECUTIVE VICE PRESIDENT | DISCRETIONARY | 5,314 | $94 | $501,695 |
| 4/27/2026 | STARKS DANIEL J | — | BUY | 10,000 | $93 | $926,537 |
| 4/24/2026 | Conroy Kevin T | — | GRANT | 2,286 | — | — |
| 4/24/2026 | Stratton John G | — | GRANT | 2,286 | — | — |
| 4/24/2026 | STARKS DANIEL J | — | GRANT | 2,286 | — | — |
| 4/24/2026 | STARKS DANIEL J | — | GRANT | 7,105 | — | — |
| 4/24/2026 | Roman Michael F | — | GRANT | 2,286 | — | — |
| 4/24/2026 | O'Grady Michael | — | GRANT | 2,286 | — | — |
| 4/24/2026 | O'Grady Michael | — | GRANT | 5,929 | — | — |
| 4/24/2026 | McKinstry Nancy | — | GRANT | 2,286 | — | — |
| Date | Insider | Title | Relationship | Shares | Filing |
|---|---|---|---|---|---|
| 4/28/2026 | — | — | — | — | SEC |
| Institution | Shares | Value ($) | Change % | Filing date |
|---|---|---|---|---|
| BlackRock | 145,793,958 | $14,968,665,708 | 100.0% | 5/13/2026 |
| BlackRock | 152,563,476 | $13,843,609,746 | 4.6% | 8/7/2026 |
| State Street | 79,575,468 | $8,170,013,300 | 100.0% | 5/15/2026 |
| State Street | 80,926,234 | $7,343,246,473 | 1.7% | 8/7/2026 |
| Morgan Stanley | 30,101,596 | $3,090,531,225 | 100.0% | 5/15/2026 |
| JP Morgan Chase | 26,767,099 | $2,727,032,277 | 100.0% | 5/13/2026 |
| Morgan Stanley | 26,611,315 | $2,414,710,960 | -11.6% | 8/13/2026 |
| Goldman Sachs | 18,604,570 | $1,688,178,719 | 22.9% | 8/14/2026 |
| Goldman Sachs | 15,142,201 | $1,554,649,814 | 100.0% | 5/15/2026 |
| JP Morgan Chase | 15,113,798 | $1,401,200,552 | -43.5% | 8/12/2026 |
| Fidelity (FMR) | 13,423,080 | $1,218,010,279 | 23.8% | 8/13/2026 |
| Fidelity (FMR) | 10,845,315 | $1,113,488,490 | 100.0% | 5/15/2026 |
| Citadel Advisors | 12,066,927 | $1,094,952,956 | 215.9% | 8/14/2026 |
| Two Sigma | 8,221,115 | $745,983,975 | 27.6% | 8/14/2026 |
| Two Sigma | 6,441,328 | $661,331,146 | 100.0% | 5/15/2026 |
| DE Shaw | 5,397,254 | $554,136,069 | 100.0% | 5/15/2026 |
| Millennium Management | 4,405,494 | $399,754,526 | 133.5% | 8/14/2026 |
| Citadel Advisors | 3,820,246 | $392,224,657 | 100.0% | 5/15/2026 |
| AQR Capital | 4,193,058 | $380,478,062 | 166.6% | 8/14/2026 |
| Millennium Management | 1,886,942 | $193,732,335 | 100.0% | 5/15/2026 |